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ABSTRACT 
 
The pathological characterization of adrenocortical cancer (ACC) is still problematic for 
several reasons, including the identification of novel markers of diagnostic or prognostic 
relevance. Among them, steroidogenic factor 1 (SF-1) deserves major interest because of its 
potential usefulness as a marker of adrenocortical derivation and of biological 
aggressiveness. Our aim was to validate its prognostic relevance in a large series of ACC, 
comparing the performance of two different commercial antibodies and investigating its 
expression in ACC variants and in comparison to clinical and pathological features. Seventy-
five (including 53 classical, 10 myxoid and 12 oncocytic) ACC cases were included in TMAs 
and analyzed for the immunohistochemical expression of SF-1 using two commercial 
antibodies, one polyclonal and one monoclonal (N1665). Nuclear SF-1 staining was assessed 
using a semi-quantitative score and correlated with ACC type and clinical pathological 
characteristics. A weak but significant correlation was found comparing the two antibodies 
with a positive rate of 88% and 58% using the monoclonal and polyclonal antibodies, 
respectively. High SF-1 expression with the N1665 antibody was positively correlated with 
high mitotic count, high Ki-67 index and high ENSAT stage, and negatively associated with 
loss of functionality and presence of oncocytic features. Moreover, high SF-1 expression with 
this same antibody was significantly associated at univariate analysis with a decreased 
survival, together with high Ki-67 and mitotic indexes, with a trend to significance confirmed 
by multivariate analysis, thus supporting the detection of SF-1 using the N1665 antibody as a 
novel prognostic marker in ACC.  
 
Keywords. adrenal cancer, SF-1, monoclonal antibody, prognosis. 
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INTRODUCTION  
 
The pathological characterization of adrenocortical carcinoma (ACC) still remains challenging 
for the pathologist for several reasons. First of all, it is a rare neoplasm (about 1 case per 
million) for which clear-cut morphological parameters to define malignancy are lacking [1]. 
Many diagnostic methods have been proposed, either based on scoring systems including 
the most frequently used Weiss system [2,3] or using alternative algorithmic approaches 
[4,5]. In addition, rare morphological variants exist, such as myxoid [6] and oncocytic [7,8] 
ACC, for which the Weiss system is not adequate due to the risk of under or overestimating 
malignancy, respectively. Moreover, even when malignancy is easily assessable, differential 
diagnosis of ACC might be uncertain from other primary adrenal (pheochromocytoma, 
PEComa) or extra-adrenal (renal cell carcinoma, melanoma, poorly differentiated metastatic 
carcinomas, retroperitoneal sarcomas) neoplasms, and immunophenotyping is not always 
conclusive. Finally, ACC is a highly aggressive malignancy and a more precise prognostic 
estimate is required. As a consequence, many complementary tools to the classical 
morphological diagnosis were proposed, generally based on specific marker 
immunodetection, and gene, miRNA or gene methylation profiling [9-14]. Among the most 
promising novel tools, Steroidogenic Factor-1 (SF-1) has been recently proposed as an 
adrenocortical-specific marker, as well as a relevant prognostic indicator in ACC [15]. In fact, 
SF-1 - which is expressed by adrenocortical cells during foetal and adult life, mostly in the 
zona glomerulosa and fasciculata - appeared as a highly sensitive (98.6%) and specific (100%) 
diagnostic marker of adrenocortical derivation and its high protein expression levels were 
also correlated with a poor prognosis. The diagnostic role of SF-1 was later confirmed by 
Sangoi and coworkers [16] on a series of 63 adrenocortical lesions, while the prognostic role 
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still needs to be validated. Aim of the present study was therefore: a) to compare the 
performance of two different SF-1 commercial antibodies in a large series of ACC; b) to 
investigate if ACC variants differ in SF-1 expression in comparison to the classical ACC; c) to 
compare SF-1 expression with several clinical and pathological features and validate its 
prognostic role in ACC patients. 
 
MATERIAL AND METHODS 
 
Tissue collection - 197 consecutive adrenocortical tumors having a Weiss score >3 [2, 3] 
were collected between 1990 and 2011 from the pathology files of the University of Turin, 
including 138 consultation cases. Among them, 75 cases had paraffin embedded tissue 
suitable for tissue microarray (TMA) construction and formed the basis of the current study 
(Table 1). The majority of these patients were treated at our Institution, which serves as a 
referral center for ACC in Italy. The histo-pathological features of 22 classical, 10 myxoid and 
12 oncocytic ACCs of this data set have already been reported [5-7]. For all cases, the clinical, 
pathological and follow up data were collected. The study received ethical approval from the 
local Review Board of our Institution. 
 
Tissue MicroArray (TMA) construction - Haematoxylin and eosin (H&E)-stained slides of the 
75 ACC were reviewed by one of us (ED) to identify three representative areas of well-
preserved morphology and no significant necrotic tissue. The corresponding areas on the 
paraffin block were marked for tissue punching. TMAs were assembled using a commercially 
available manual tissue puncher/arrayer (Quick-RAYTM tissue arrayer; Bio-Optica, Milan, 
Italy) according to the manufacturer’s instructions. To minimize the number of inadequate 
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cases and to increase concordance rates among different cores, three cores with a diameter 
of 2 mm were punched from each tissue block and arrayed into the recipient paraffin block. 
TMAs also included two cores of different control tissues (adrenal cortex, adrenal medulla, 
kidney). 
 
Immunohistochemistry – Serial five µm-thick paraffin sections from the constructed TMA 
blocks were processed for immunohistochemistry. Two commercially available antibodies 
against SF-1 were employed, the first polyclonal (diluted 1/500; Upstate, Millipore, Billerica, 
MA, USA) and the second monoclonal (clone N1665, diluted 1/100; Perseus Proteomics, 
Tokyo, Japan). The proliferative index was evaluated in parallel with MIB-1 antibody to Ki-67 
(diluted 1/150; Dako Cytomation, Glostrup, Denmark). Sections were deparaffinized and 
rehydrated in ethanol. For antigen retrieval, a pressure cooker treatment for 5 minutes at 
125°C, followed by a quick 10-second step at 90°C was performed in ethylenediamine 
tetraacetic acid (EDTA) buffer (pH 8.0) for all antibodies. Samples were allowed to cool to 
room temperature before incubation with 3% hydrogen peroxide in Tris-buffered saline 
(TBS) for 10 min to quench endogenous peroxidase activity. Subsequently, sections were 
incubated for one hour at 37°C with SF-1 antibodies, or for one hour at room temperature 
for Ki-67. A biotin-free, dextran chain-based detection system (EnVysion, Dako) was used 
according to a standard protocol and using diaminobenzidine as the chromogen. Finally, 
slides were counterstained with hematoxylin, dehydrated, and mounted. TMA cores of 
normal tissue including adrenal cortex, adrenal medulla and kidney served as appropriate 
internal positive (the former) and negative (the others) controls. 
 
Staining interpretation and scoring system - All slides were analyzed independently by two 
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of us (ED, MV), who included in the analysis only samples with two or three evaluable cores 
after the immunostaining. Staining was assessed for each core using a semiquantitative 
scoring system based on the evaluation of nuclear staining, as follows:  score 0= no staining; 
score 1= focal (<50% of the core) staining; score 2= diffuse (>50% of the core) staining. An 
overall score for each case was calculated as the mean of the assessed cores. In case of 
discrepancies, slides were reviewed at a multihead microscope and a consensus was 
reached. For descriptive purposes, all cases with an overall score different from 0 were 
considered positive. Moreover, for subsequent statistical analysis, cases were then 
categorized as “negative/low“ or “high” expression according to the mean score value of the 
overall population (corresponding to 1.11).  
 
Statistical analysis - Correlation between the two SF-1 antibodies was made using a two-
tailed Spearman’s test. Clinical and pathological characteristics were compared to staining 
patterns of the two SF-1 antibodies by Fisher’s exact or Chi-square and Student’s t tests, for 
categorical and continuous variables, respectively. To analyze the prognostic impact of all 
clinical and pathological variables considered, univariate overall survival analysis was based 
on the Kaplan–Meier product limit estimate of survival distribution. Clinical pathological 
parameters considered in overall survival analysis included: sex, age, hormonal secretion, 
weight, size, Weiss score, Ki67 index, mitotic index, ENSAT stage and the reactivity to SF-1 
antibodies. Unadjusted differences between survival curves were tested using the log rank 
test. All parameters with a significant impact on survival at univariate analysis were 
considered for multivariate analysis using the Cox proportional hazard model. Statistical 
significance was set at p<0.05. All tests were performed using GraphPad Prism version 5.0 
and STATISTICA version 7.0 softwares. 
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RESULTS 
 
Clinical and pathological data and SF-1 protein expression – Clinical and pathological data 
of the ACC series analyzed are summarized in Table 1. All tumors had a Weiss score >3 and 
were defined as malignant also using the “reticulin algorythm“ [5]. All tumors had reticulin 
framework disruption in the presence of at least one of either high mitotic count or necrosis 
or vascular invasion. 
SF-1 protein expression (including all cases with a mean case score different from 0) was 
detected in 64 of 73 evaluable ACC cases (88%) by the monoclonal antibody and in 42 of 72 
(58%) by the polyclonal antibody. Both antibodies tested positive at the nuclear level in 
normal adrenocortical tissue (Figure 1) and negative in control tissues from adrenal medulla 
and kidney. A general more intense immunoreactivity, both in normal and neoplastic 
adrenocortical tissues, was observed using the SF-1 monoclonal antibody. An additional 
weak and occasional cytoplasmic immunoreactivity was observed when the SF-1 polyclonal 
antibody was used, only. A significant, although weak, positive correlation was found 
comparing the scoring results obtained with the two antibodies (Spearman r: 0.4786, 95% 
confidence interval: 0.2696 -0.6446; p-value < 0.0001). 
 
Correlation of SF-1 expression with clinical and pathological variables (Table 2) – High SF-1 
nuclear expression, as detected by using the polyclonal antibody, was associated to female 
sex and high mitotic rate. By contrast, high SF-1 nuclear expression, as detected by using the 
monoclonal antibody, was positively correlated with high mitotic count, high Ki-67 index and 
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advanced ENSAT stage. Interestingly, SF-1 protein using the monoclonal antibody was also 
differentially expressed in ACC variants, being negative or low in the majority of cases of the 
oncocytic type, and a higher rate of reactivity was observed in functioning tumors, too, 
although not significantly associated with the type of hormone secreted.  
  
Correlation of SF-1 expression with disease outcome (Table 3) - Univariate analysis showed 
that high Ki-67 proliferation and high mitotic indexes were associated to shorter overall 
survival. Moreover, high SF-1 expression, as detected by means of the monoclonal antibody 
was associated with an increased risk of disease-related death (HR: 3.924, p=0.0036) and 
decreased survival (median survival of 27 vs 82 months in cases with high and negative/low 
expression, respectively) (Figure 2). A trend to significance was maintained at multivariate 
analysis (p=0.117) that showed mitotic index as the most powerful prognostic indicator in 
our series (p=0.028). By contrast, SF-1 expression as detected by the polyclonal antibody did 
not show any prognostic relevance in the current ACC series. 
 
 
DISCUSSION 
 
In the present report, we investigated the expression of SF-1 in a large series of ACC. The aim 
of our study was to validate the utility of SF-1 as a prognostic marker, testing the 
immunohistochemical performance of two different commercially available antibodies and 
comparing its expression with several clinical and pathological parameters.  The first 
antibody we employed is a monoclonal reagent which has been previously demonstrated to 
be highly specific and sensitive for the recognition of adrenocortical tissues as well as 
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prognostic in ACC patients [15,16]. The second antibody is a polyclonal antibody never 
tested in ACC samples, so far, to the best of our knowledge.  
Among several immunohistochemical and molecular markers recently proposed in ACC, SF-1 
deserves a major interest for the dual potential implications in the diagnostic and prognostic  
characterization of ACC. In fact, as already mentioned above, SF-1 expression is a strong tool 
to determine the adrenocortical derivation of a given tumoral lesion, irrespective of its 
benign or malignant nature, being expressed by few other steroidogenic tissues only (such as 
ovarian stroma or steroid hormone producing testicular cells). Although we did not design 
this study to validate this specific diagnostic utility, we could confirm that SF-1 is expressed 
in a relevant percentage of ACC, thus being a highly sensitive tool to take ACC apart from 
other mimickers in the adrenal gland. However, the expression rates were different when 
considering the two different antibodies; in fact, it raised from 58% positive cases only with 
the polyclonal serum to 88% with the monoclonal antibody. This latter figure is slightly lower 
than that originally reported by Sbiera (98%) [15], but comparable to what reported recently 
on TMA material (86%) [16], using the same monoclonal antibody herein employed.  
Indeed, we mainly focused our analysis of SF-1 expression in a cohort of ACC with the 
specific aim to validate its prognostic value and investigate different SF-1 expression profiles 
as compared to clinical and pathological features. In the original paper by Sbiera and 
coworkers [15] the sub-analysis of SF-1 distribution was limited to sex, age, tumor stage and 
hormone secretion, apparently with no specific correlation. In our series, the two different 
antibodies gave heterogeneous results as a possible consequence of their poor reciprocal 
correlation. In fact, while the polyclonal SF-1 antibody was associated to sex and mitotic 
index only, the monoclonal antibody showed a wider association with “high grade” clinical 
and pathological parameters that is to say characteristics predictive of worse prognosis. High 
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SF-1 expression, as detected with the monoclonal antibody, was positively correlated with 
advanced ENSAT stage, high proliferation and mitotic index, and high Weiss score values. 
These data are consistent with previous studies showing that SF-1 over-expression triggers 
proliferation of ACC cells and induces adrenocortical tumor formation in mice [17] and with 
in vitro observations that specific SF-1 antagonists are capable to decrease proliferation in 
ACC cell models [18]. Moreover, we originally found that SF-1 was differentially expressed in 
ACC histological types, since it was slightly more expressed in myxoid ACC (6/10 cases) 
compared to the conventional ones (14/51 cases), and it was very infrequently reactive in 
the oncocytic variant of ACC (1/12 cases). This observation might possibly reflect the 
generally lower growth potential in this latter group as compared to classical ACC [7], but 
alternative mechanisms linked to the specific metabolic/functional properties of oncocytic 
cell and tumors might be also active. Interestingly, we also observed a striking difference in 
the prevalence of SF-1 over-expression according to the functional status of the tumors 
analyzed: SF-1 was detected at a high expression level in nearly 40% of functioning but in 9% 
only of non-functioning tumors. Although this is apparently in contrast with the previous 
observation by Sbiera [15], it is quite reasonable to assume that the expression levels of SF-
1, whose properties are related to steroidogenesis [19], might be proportional to hormonal 
production and secretion by tumor cells. It is worth to notice that the prevalence of 
functional tumors in the oncocytic and myxoid cases was opposite, since 3/7 and 5/6 were 
hormone secreting in the oncocytic and myxoid group of tumors, respectively. Therefore, it 
should be considered that this finding might be, at least partially, responsible of the 
correlation between SF-1 expression and histologic variant. In practical terms, the present 
data show that SF-1 expression may be a useful diagnostic tool, proven that the results are 
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integrated in an  appropriate morphological and clinical context, since its sensitivity might be 
lower in specific ACC variants and in non-functioning tumors.  
Finally, we validated the impact of SF-1 expression levels on prognosis of the current ACC 
series. At univariate analysis, high expression levels of SF-1, as detected by the N1665 
monoclonal antibody, were closely correlated with survival, together with mitotic and 
proliferation indexes. At multivariate analysis, mitotic count was the only significant 
independent parameter in our series, but a trend to significance was maintained for SF-1, 
too. Although methodological differences (SF-1 scoring system and cut off value selection, 
size of the case series, patients’ characteristics) are possibly responsible for the slightly lower 
statistical power of SF-1 as compared to that reported by Sbiera [15], our data are 
supportive of the potential role of SF-1 as a prognostic marker in ACC. For this reason, its 
inclusion in a minimal set of markers for the characterization of ACC samples is advisable.  
In conclusion, SF-1 is detectable in a high percentage of ACC and its high expression levels 
correlate with high-grade features, histological type, functional status and adverse outcome. 
The N1665 monoclonal antibody proved superior to commercial polyclonal antisera and its 
use is therefore currently advisable in the clinical practice for both diagnostic and prognostic 
purposes.  
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Table 1. Clinical and pathological features of 75 ACC cases included in the Tissue 
MicroArrays.  
Parameter  
M/F ratio 32/43 
Age, mean (years) 46 [20-79] 
Functional status (Not known:  15) Not functioning: 23 
Functioning: 37* 
Size, mean (cm) 11. 5 [2-30] 
Weight, mean (grams) 481 [8-3200] 
Histologic type Conventional: 53  
Myxoid: 10  
Oncocytic: 12 
Weiss score distribution 3-4: 15 
5-6: 24 
7-8-9: 36 
ENSAT stage (Not known:  20) 1-2: 20 
3-4: 35 
Follow up (lost to FU:  6) NED/DOC: 21 
AWD: 15 
DOD: 33 
Median overall survival  (months) 53 
Abbreviations: ACC, adrenocortical carcinoma; M, male; F, female; *: functionality included 
the presence of  predominant cortisol (28 cases, including 1 oncocytic and 5 mixoid tumors), 
aldosteron (6 cases, including 1 oncocytic tumor) and androgens (3 cases, including 1 
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oncocytic tumor) secretion; FU, follow up; NED, no evidence of disease; DOC, died of other 
cause; AWD, alive with disease; DOD, died of disease. 
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Table 2. SF-1 immunohistochemistry: clinical and pathological correlates in ACC 
Parameter SF1 polyclonal^ SF1 monoclonal^ 
negative/low high p negative/low high p 
Sex M 
F 
24 
18 
8 
22 
0.016 25 
27 
6 
15 
0.19 
Age ≤45 
>45 
21 
21 
17 
13 
0.64 29 
23 
10 
11 
0.61 
Histologic 
type 
conventional 
myxoid 
oncocytic 
31 
4 
7 
19 
6 
5 
0.44 37 
4 
11 
14 
6 
1 
0.026 
Functional 
status 
functioning 
not functioning 
21 
16 
14 
6 
0.40 22 
21 
14 
2 
0.015 
Type of 
hormone 
cortisol 
aldosteron/androgens 
16 
5 
10 
4 
1.00 16 
6 
11 
3 
1.00 
Size* <11 
>11 
15 
15 
11 
8 
0.77 21 
17 
9 
10 
0.59 
Weight* <260 
>260 
19 
24 
11 
11 
0.59 16 
17 
10 
6 
0.38 
Mitotic 
index 
x50HPF* 
<11 
>11 
29 
14 
11 
18 
0.017 33 
19 
7 
14 
0.036 
Ki-67 index* <20 
>20 
18 
16 
10 
15 
0.43 26 
15 
2 
17 
0.0002 
Weiss score 3-4 8 6 0.99 14 0 0.024 
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5-6 
7-8-9 
14 
20 
10 
14 
16 
22 
7 
14 
ENSAT stage 1-2 
3-4 
12 
18 
7 
14 
0.77 18 
20 
2 
14 
0.029 
Disease 
status 
NED/DOC 
AWD 
DOD 
15 
6 
19 
6 
8 
12 
0.24 17 
10 
20 
3 
5 
12 
0.21 
Abbreviations: SF-1 polyclonal: Upstate, Millipore; SF-1 monoclonal: clone N1665, Perseus; 
M, male; F, female; NED, not evidence of disease; HPF, high power field; DOC, died of other 
cause; AWD, alive with disease; DOD, died of disease. *: median value. ^: SF-1 polyclonal: 72 
cases evaluable; SF-1 monoclonal: 73 cases evaluable 
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Table 3. Univariate overall survival analysis. 
Parameter HR 95% CI p 
Female sex 1.064 0.5317-2.129 0.8608 
Age <45 0.9039 0.4529-1.804 0.7744 
Presence of hormonal activity  1.406 0.6741-2.933 0.3635 
Weight >260 0.8803 0.3990-1.942 0.7992 
Size >11 cm 1.257 0.5852-2.699 0.5577 
Weiss score >7 1.333 0.6639-2.676 0.4189 
Ki-67 >20%* 2.366 1.095-5.112 0.0285 
Mitotic index x 50HPF>11* 3.482 1.608-7.538 0.0015 
ENSAT Stage 3-4 1.611 0.7724-3.360 0.2036 
High SF-1 levels (polyclonal) 1.162 0.5522-2.443 0.6931 
High SF-1 levels (monoclonal)* 3.924 1.561-9.860 0.0036 
Abbreviations: SF-1 polyclonal: Upstate, Millipore; SF-1 monoclonal: clone N1665, Perseus; 
*: parameters included in multivariate analysis: mitotic index: p=0.028; Ki-67: p=0.342; SF-1 
monoclonal: p=0.117 
 
 
 
21 
 
FIGURES  
 
Figure 1. SF-1 expression in normal adrenal cortex and ACC samples using a polyclonal and a 
monoclonal antibody (immunoperoxidase; original magnification 200x for all images) 
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Figure 2. Kaplan Meier curves representing overall survival distribution in ACC patients with 
negative/low vs high SF-1 protein expression levels. 
 
 
 
